Educated 30-45-year-old professionals who have already failed SSRIs, CBT, and other conventional treatments and are now actively researching or paying out-of-pocket for psilocybin, MDMA, or ketamine therapy to resolve persistent PTSD, treatment-resistant depression, or severe anxiety. Insurance covers almost none of it, so they spend $3,000-$20,000+ per treatment cycle — and the support layer around preparation, vetting, and integration is almost entirely unbuilt.
On April 18, 2026, President Trump signed an executive order fast-tracking FDA review of psychedelic therapies and allocating $50 million in federal funds — the first White House-level signal that drives mainstream patient awareness and reduces stigma overnight, pulling millions of treatment-resistant patients off the fence (White House, April 2026).
The psychedelic-assisted therapeutics market hit $6.28 billion in 2026 and is growing at a 14-16% CAGR toward $18+ billion by 2034 — sustained double-digit growth this fast means new buyers are entering every quarter, not just existing buyers spending more (ResearchIntelo / Research and Markets, 2026).
Compass Pathways filed a rolling NDA for COMP360 psilocybin targeting Q4 2026, with FDA priority review vouchers compressing the timeline to 1-2 months — an imminent first-ever classic psychedelic FDA approval will trigger a massive wave of newly eligible patients who need vetted therapist lists, preparation guides, and integration coaching before and after their first session (Medical Daily / Top Doctor Magazine, June/May 2026).
The exact words they type into Google.
Create a free account to unlock the full breakdown — all 3 ideas and every community map on the site.
Free forever. No credit card. Takes 20 seconds.
Also in Health. Sorted by how fast they are growing.
Med spa owner-operators — NPs, PAs, and physicians running revenue-generating aesthetic practices — are facing a wave of new state laws, active enforcement sweeps, and license revocation risk. With 2026 marking the first year of direct legislative regulation in multiple states, owners need operational compliance infrastructure now: the right agreements, SOPs, and physician oversight structures to protect their license and revenue stream.
Affluent adults aged 35–60 who already biohack their health are self-administering injectable peptides to lose fat, recover faster, slow aging, and boost performance. They pay $200–$1,000 per month out of pocket with no insurance coverage, yet have almost no trusted tools to verify product purity, guide protocol decisions, or track results.
People with health insurance who just got a denial letter and want to fight it but feel buried in paperwork and jargon. AI tools now generate the full appeal letter in under 60 seconds, removing the only real barrier that stopped most people from winning money that was already owed to them.
College-educated women ages 25–55 who spent years getting dismissed by conventional doctors are now self-directing their own SIBO and gut recovery protocols through stacked supplements, at-home breath tests, and functional medicine telehealth. Their core goal is getting their daily life back after years of debilitating bloating, pain, and misdiagnosis — not wellness optimization.